Richard Pittner

With over 25 years of expertise in the discovery, validation, development and in-licensing of novel therapeutics and technologies, Dr. Pittner is currently a consultant and is active as a startup advisor and technology incubator in San Diego. Dr. Pittner co-founded OXT-Therapeutics, focused on the development of an oxytocin-based portfolio for metabolic disease, where he is acting Chief Development Officer. He co-founded an incubator group, BioShore Partners, which has recently progressed 2 product concepts into newly incorporated startups - Abvance and Aquros. Additionally, he is an advisor (acting SVP) to CPC/Xinbang in evaluating/in-licensing peptide therapeutic programs for the Chinese market.

Dr. Pittner worked several years at Eli Lilly and and Pfizer where he led External R&D efforts, identifying, evaluating and in-licensing external drug assets. Previously, he worked for 15 years at Amylin as Head of Discovery Biology developing novel peptide therapeutics for metabolic diseases (including Byetta and Symlin). Dr. Pittner holds a number of patents, is the co-author of over 40 publications and received his Ph.D from University of Nottingham.